People · Operator
Named in public records as an officer, director or promoter · active 2019–2023 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cambrian BioPharma Inc | — | Pharmaceuticals | Series C | $148.4M | $293.1M | 2019 |
| Isterian Biotech, Inc. | — | Biotechnology | Seed | $3.0M | $133.2M | 2020 |
| Telos Biotech Inc. | — | Biotechnology | Pre-Seed | $1.4M | $1.4M | 2019 |
James G. Peyer at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James G. Peyer on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Sebastian Aguiar Brunemeier | 1 | 2 |
| Mohammad Ehsan Sayed | 1 | 1 |
| Jerry William Shay | 1 | 1 |
| Christian G. Angermayer | 1 | 1 |
| Maryanna G. Saenko | 1 | 1 |
| Paul G. Farr | 1 | 1 |
| Brenton G. Saunders | 1 | 1 |
| Enzo Ehsan Tedone | 1 | 1 |
| Christian G. Angermeyer | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.